pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
the cabinet
Drugs
8,127
products tracked ·
368
matching
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
view
list
cards
Phase 3
RTX-015
Retinitis Pigmentosa (Retinitis)
Ray Therapeutics Inc
0
catalysts
Phase 2
RY-104
Wet (Neovascular / Exudative) Macular Degeneration
Neuracle Genetics Inc
0
catalysts
Phase 2
SAR-402663
Wet (Neovascular / Exudative) Macular Degeneration
$SNY
Sanofi
0
catalysts
Phase 2
SAR-446597
← prev
page 8 of 13
next →
131
Pain
89
Neurology
1
Geographic Atrophy
$SNY
Sanofi
0
catalysts
Phase 2
SB-007
Juvenile Macular Degeneration (Stargardt Disease)
Splice Bio SL
0
catalysts
Phase 2
SHJ-002
Myopia
Sunhawk Vision Biotech Inc
0
catalysts
Phase 2
SKG-0106
Wet (Neovascular / Exudative) Macular Degeneration
Skyline Therapeutics (Shanghai) Co Ltd
0
catalysts
Phase 2
SPVN-06
Retinitis Pigmentosa (Retinitis)
SparingVision SAS
0
catalysts
Phase 2
STMC-103H
Allergies
Siolta Therapeutics Inc
0
catalysts
Preclinical
Stem Cell Therapy for Ophthalmology
University of California Los Angeles
0
catalysts
Marketed
Syfovre
Syfovre (pegcetacoplan)
Geographic Atrophy
$APLS
Apellis Pharmaceuticals, Inc.
0
catalysts
Phase 2
TH-103
Wet (Neovascular / Exudative) Macular Degeneration
$KLRS
Kalaris Therapeutics, Inc.
0
catalysts
Phase 1
TRE-515
Ovarian Cancer
Trethera Corp
0
catalysts
Preclinical
TREM-1 Inhibitors
Retinopathy Of Prematurity
Signablok Inc
0
catalysts
Phase 2
TTHX-1114
Fuchs Endothelial Corneal Dystrophy (FECD)
Trefoil Therapeutics LLC
0
catalysts
Phase 2
Umedaptanib Pegol
Wet (Neovascular / Exudative) Macular Degeneration
Ribomic Inc
0
catalysts
Phase 2
VG-801
Unspecified Ophthalmological Disorders
VeonGen Therapeutics GmbH
0
catalysts
Phase 2
VP-001
Retinitis Pigmentosa (Retinitis)
PYC Therapeutics Ltd
0
catalysts
Phase 2
VVN-001
Keratoconjunctivitis Sicca (Dry Eye)
VivaVision Biotech Ltd
0
catalysts
Phase 2
VVN-461
Ocular Inflammation
VivaVision Biotech Ltd
0
catalysts
Preclinical
XLRS Gene Therapy Program
Retinal Degeneration
TeamedOn International Inc
0
catalysts
Phase 2
YPP-10
Keratoconjunctivitis Sicca (Dry Eye)
Yuyu Pharma Inc
0
catalysts
Marketed
Zylet
Zylet ((loteprednol etabonate + tobramycin))
Bacterial Conjunctivitis
$BLCO
Bausch & Lomb Corp
0
catalysts
Marketed
aceclidine
Vizz (aceclidine)
Presbyopia
$LENZ
LENZ Therapeutics, Inc.
0
catalysts
Marketed
acetazolamide sodium
Acetazolamide Sodium (acetazolamide sodium)
Closed-Angle Glaucoma
X-GEN Pharmaceuticals DJB Inc
0
catalysts
Marketed
acetylcholine chloride
Miochol-E (acetylcholine chloride [INN])
Miosis
$BLCO
Bausch & Lomb Corp
0
catalysts
Marketed
acoltremon
Tryptyr (acoltremon)
Keratoconjunctivitis Sicca (Dry Eye)
$ALC
ALCON INC
0
catalysts
Marketed
adalimumab biosimilar
Simlandi (adalimumab-ryvk)
Hidradenitis Suppurativa
$ALVO
Alvotech
0
catalysts
Marketed
alcaftadine
Alcaftadine (alcaftadine)
Allergic Conjunctivitis
Fosun Pharma USA Inc
0
catalysts
Marketed
apraclonidine hydrochloride
Iopidine (apraclonidine hydrochloride)
Ocular Hypertension
$HROW
HARROW, INC.
0
catalysts
